Source: Annual Congress 2006 - Miscellaneous respiratory infections II
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
I. Marincu, C. Oancea, S. Mihaicuta, V. Tudorache, L. Marincu (Timisoara, Romania). The efficiency of levofloxacin in the therapy of community acquired pneumonia. Eur Respir J 2006; 28: Suppl. 50, 146

Member's Comments

No comment yet.

Related content which might interest you: Cost-efficacy analysis of cefixime switch therapy in the treatment of community acquired pneumonia Source: Eur Respir J 2006; 28: Suppl. 50, 350s Year: 2006 Comparison of conventional and sequential antibiotic therapy of community-acquired pneumonia with levofloxacin and moxifloxacin Source: Annual Congress 2007 - Antibiotic treatment in community-acquired pneumonia Year: 2007 Cost-effective antibiotic management of community acquired pneumonia Source: ISSN=1025-448x, ISBN=1-904097-32-4, page=198 Year: 2004 Effectiveness of the empirical administration of antibiotics in community acquired pneumonia (CAP) Source: Annual Congress 2007 - Antibiotic treatment in community-acquired pneumonia Year: 2007 Monotherapy with β-lactamic antibiotics or macrolides vs their combination for the treatment of community acquired pneumonia (CAP) Source: Annual Congress 2008 - Lower respiratory tract infection: from outbreak to prognostic tests Year: 2008 Switching of antimicrobial agents in the therapy of community acquired pneumonia Source: Annual Congress 2009 - Aetiology and treatment of community-acquired pneumonia Year: 2009 Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia Source: Eur Respir J 2003; 21: 135-143 Year: 2003 The use of piperacillin/tazobactam for treatment of pneumonia in neutropenic patients Source: Annual Congress 2010 - Aetiology of lower respiratory tract infections and treatment in special situations Year: 2010 Using roncoleukine in basic therapy of patients with community acquired pneumonia Source: Eur Respir J 2002; 20: Suppl. 38, 443s Year: 2002 Efficacy and safety of levofloxacin treatment of community-acquired pneumonia in hospitalized patients Source: Eur Respir J 2005; 26: Suppl. 49, 637s Year: 2005 Practical treatment of community acquired pneumonia (CAP) with outpatient parenteral antibiotic therapy (OPAT) and switch therapy: CTRX and LVFX Source: Annual Congress 2008 - Diagnostic tests in lower respiratory tract infections Year: 2008 Cost-effectiveness of full-course oral levofloxacin in severe community-acquired pneumonia Source: Eur Respir J 2004; 24 : 644-648 Year: 2004 Importance of appropriate initial antibiotic therapy and de-escalation in the treatment of nosocomial pneumonia Source: Eur Respir Rev 2007; 16: 33-39 Year: 2007 Improving outcome in elderly patients with pneumonia Source: Annual Congress 2005 - Antibiotic therapy: short- and long-term outcomes in LRTI Year: 2005 The effect of addition of macrolide to a beta-lactam antibiotic on treatment success in patients with moderately severe community acquired pneumonia Source: Annual Congress 2010 - Aetiology of lower respiratory tract infections and treatment in special situations Year: 2010 Tigecycline vs levofloxacin for the treatment of community-acquired pneumonia (CAP): EU experience Source: Annual Congress 2008 - Treatment and outcome in hospitalised patients with community-acquired pneumonia Year: 2008 Comparisom between imipenem/cilastatin and cefepim for treatment of severe nosocomial pneumonia Source: Eur Respir J 2007; 30: Suppl. 51, 53s Year: 2007 Frequency of antibiotic resistance and outcomes in severe community acquired pneumonia due to Streptococcus pneumoniae Source: Annual Congress 2009 - Aetiology and treatment of community-acquired pneumonia Year: 2009 The approach to antibiotic treatment in community-acquired pneumonia Source: Annual Congress 2008 - MP14 - The approach to antibiotic treatment in community-acquired pneumonia Year: 2008 Hospital-acquired pneumonia: microbiological data and potential adequacy of antimicrobial regimens Source: Eur Respir J 2002; 20: 432-439 Year: 2002